JP6743320B1 - 抗ｃｄ１３７抗体 - Google Patents

抗ｃｄ１３７抗体 Download PDF

Info

Publication number
JP6743320B1
JP6743320B1 JP2020505392A JP2020505392A JP6743320B1 JP 6743320 B1 JP6743320 B1 JP 6743320B1 JP 2020505392 A JP2020505392 A JP 2020505392A JP 2020505392 A JP2020505392 A JP 2020505392A JP 6743320 B1 JP6743320 B1 JP 6743320B1
Authority
JP
Japan
Prior art keywords
cancer
seq
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527356A (ja
Inventor
クリストファー・カール・フライ
マイケル・デウェイン・カロス
ヘレン・コタニデス
ステファニー・リン・サンデファー
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Application granted granted Critical
Publication of JP6743320B1 publication Critical patent/JP6743320B1/ja
Publication of JP2020527356A publication Critical patent/JP2020527356A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L7/00—Arrangements for synchronising receiver with transmitter
    • H04L7/04—Speed or phase control by synchronisation signals
    • H04L7/10—Arrangements for initial synchronisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/25—Arrangements specific to fibre transmission
    • H04B10/2575—Radio-over-fibre, e.g. radio frequency signal modulated onto an optical carrier
    • H04B10/25752—Optical arrangements for wireless networks
    • H04B10/25753—Distribution optical network, e.g. between a base station and a plurality of remote units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020505392A 2017-08-01 2018-07-25 抗ｃｄ１３７抗体 Active JP6743320B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539687P 2017-08-01 2017-08-01
US62/539,687 2017-08-01
PCT/US2018/043632 WO2019027754A1 (en) 2017-08-01 2018-07-25 ANTI-CD137 ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020128427A Division JP7257364B2 (ja) 2017-08-01 2020-07-29 抗ｃｄ１３７抗体

Publications (2)

Publication Number Publication Date
JP6743320B1 true JP6743320B1 (ja) 2020-08-19
JP2020527356A JP2020527356A (ja) 2020-09-10

Family

ID=63165504

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505392A Active JP6743320B1 (ja) 2017-08-01 2018-07-25 抗ｃｄ１３７抗体
JP2020128427A Active JP7257364B2 (ja) 2017-08-01 2020-07-29 抗ｃｄ１３７抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020128427A Active JP7257364B2 (ja) 2017-08-01 2020-07-29 抗ｃｄ１３７抗体

Country Status (25)

Country Link
US (3) US10906983B2 (enExample)
EP (2) EP3661544B1 (enExample)
JP (2) JP6743320B1 (enExample)
KR (2) KR20210158420A (enExample)
CN (1) CN111182919B (enExample)
AU (2) AU2018311804B2 (enExample)
BR (1) BR112020001441A2 (enExample)
CA (2) CA3146758A1 (enExample)
CL (1) CL2020000233A1 (enExample)
CO (1) CO2020001050A2 (enExample)
CR (1) CR20200042A (enExample)
DO (1) DOP2020000020A (enExample)
EA (1) EA202090204A1 (enExample)
EC (1) ECSP20007663A (enExample)
ES (1) ES2912651T3 (enExample)
IL (1) IL272349B2 (enExample)
JO (1) JOP20200016B1 (enExample)
MA (1) MA49749A (enExample)
MX (1) MX2020001351A (enExample)
PE (1) PE20200839A1 (enExample)
PH (1) PH12020500225A1 (enExample)
SA (1) SA520411186B1 (enExample)
SG (1) SG11202000747VA (enExample)
UA (1) UA128388C2 (enExample)
WO (1) WO2019027754A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020182492A (ja) * 2017-08-01 2020-11-12 イーライ リリー アンド カンパニー 抗ｃｄ１３７抗体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN112020517B (zh) * 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
KR20240017090A (ko) * 2018-03-23 2024-02-06 일라이 릴리 앤드 캄파니 항-pd-1 항체와의 조합을 위한 항-cd137 항체
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112021026309A2 (pt) 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
IL295382B1 (en) * 2020-02-12 2026-08-01 Chugai Seiyaku Kk Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2022111571A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞培养基及其应用
WO2024179465A1 (zh) 2023-02-27 2024-09-06 上海君赛生物科技有限公司 表达膜结合细胞因子的肿瘤浸润淋巴细胞
KR20250104655A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치
KR20250104669A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 선택 가이드 정보 제공 방법 및 그 장치
KR20250132789A (ko) 2024-02-29 2025-09-05 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3183269A2 (en) 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
CR20200042A (es) * 2017-08-01 2020-03-03 Lilly Co Eli Anticuerpos anti-cd137

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020182492A (ja) * 2017-08-01 2020-11-12 イーライ リリー アンド カンパニー 抗ｃｄ１３７抗体

Also Published As

Publication number Publication date
MA49749A (fr) 2021-03-24
SA520411186B1 (ar) 2025-06-29
CA3071383C (en) 2022-04-12
JP2020182492A (ja) 2020-11-12
NZ761548A (en) 2024-07-05
EP3661544A1 (en) 2020-06-10
PH12020500225A1 (en) 2020-11-09
EP3661544B1 (en) 2022-04-13
SG11202000747VA (en) 2020-02-27
JOP20200016B1 (ar) 2022-10-30
JP2020527356A (ja) 2020-09-10
IL272349A (en) 2020-03-31
JP7257364B2 (ja) 2023-04-13
EP4070811A1 (en) 2022-10-12
IL272349B1 (en) 2024-05-01
PE20200839A1 (es) 2020-08-13
US12453771B2 (en) 2025-10-28
CL2020000233A1 (es) 2020-07-31
MX2020001351A (es) 2020-03-09
KR20210158420A (ko) 2021-12-30
US20200377607A1 (en) 2020-12-03
CA3071383A1 (en) 2019-02-07
KR102344620B1 (ko) 2022-01-03
ES2912651T3 (es) 2022-05-26
US20230279134A1 (en) 2023-09-07
CN111182919B (zh) 2023-07-07
JOP20200016A1 (ar) 2020-01-28
KR20200023439A (ko) 2020-03-04
AU2018311804B2 (en) 2021-09-02
AU2018311804A1 (en) 2020-02-13
CR20200042A (es) 2020-03-03
WO2019027754A1 (en) 2019-02-07
US10906983B2 (en) 2021-02-02
ECSP20007663A (es) 2020-06-30
US20260109775A1 (en) 2026-04-23
AU2021277707A1 (en) 2021-12-23
CN111182919A (zh) 2020-05-19
UA128388C2 (uk) 2024-07-03
EA202090204A1 (ru) 2020-05-22
CO2020001050A2 (es) 2020-02-18
DOP2020000020A (es) 2020-02-28
CA3146758A1 (en) 2019-02-07
IL272349B2 (en) 2024-09-01
BR112020001441A2 (pt) 2020-08-04

Similar Documents

Publication Publication Date Title
JP7257364B2 (ja) 抗ｃｄ１３７抗体
US20250333525A1 (en) Anti-cd137 antibodies for combination with anti-pd-1 antibodies
JP7059388B2 (ja) 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
US11512134B2 (en) Anti-CD137 antibodies
HK40081907A (en) Anti-cd137 antibodies
HK40019208B (en) Anti-cd137 antibodies
HK40045294B (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
HK40045294A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
EA043217B1 (ru) Анти-cd137 антитела

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200304

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200304

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200729

R150 Certificate of patent or registration of utility model

Ref document number: 6743320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250